Everything About Navitoclax (ABT-263)
What is Navitoclax?
Navitoclax, also known by its research code ABT-263, is a potent, orally bioavailable small-molecule inhibitor targeting the B-cell lymphoma-2 (Bcl-2) family of anti-apoptotic proteins.
Developed by Abbott Laboratories (now AbbVie) in collaboration with Genentech, Navitoclax has emerged as a critical tool in oncology research, particularly for studying apoptosis (programmed cell death) in cancer cells.
Chemical Profile:
CAS Number: 923564-51-6
Molecular Formula: C₄₅H₅₄ClN₃O₆S₂
Molecular Weight: 868.58 g/mol
Navitoclax inhibits Bcl-2, Bcl-xL, and Bcl-w proteins, which cancer cells overexpress to evade apoptosis.
Its development marked a significant advancement in targeting the intrinsic apoptosis pathway, offering a novel strategy for combating resistant malignancies.
What is Navitoclax Used For?
Navitoclax is primarily utilized in preclinical and translational cancer research, with applications spanning:
Hematologic Malignancies:
Chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and lymphoma.
Solid Tumors:
Small-cell lung cancer (SCLC), breast cancer, and colorectal cancer.
Drug Resistance Studies:
Investigating mechanisms of resistance to chemotherapy and targeted therapies.
Combination Therapy Development:
Synergizing with agents like Venetoclax (ABT-199) or chemotherapy to enhance efficacy.
Key Research Applications:
Apoptosis pathway analysis.
In vivo tumor xenograft models.
High-throughput screening for drug synergy.
How Navitoclax Works (Mechanism of Action)
Navitoclax disrupts cancer cell survival by binding to anti-apoptotic Bcl-2 family proteins.
Here’s a step-by-step breakdown:
Binding to Bcl-2 Proteins: Navitoclax’s structure enables it to occupy the hydrophobic groove of Bcl-2, Bcl-xL, and Bcl-w, thereby preventing these proteins from sequestering pro-apoptotic proteins such as BIM and BAX.
Release of Pro-Apoptotic Factors: Freed BIM/BAX proteins permeabilize mitochondrial membranes, releasing cytochrome c into the cytoplasm.
Caspase Activation: Cytochrome c triggers the caspase cascade (e.g., caspase-3, caspase-9), leading to programmed cell death.
Why This Matters: Unlike chemotherapy, Navitoclax selectively targets the survival mechanism of cancer cells, reducing off-target toxicity in both in vitro and in vivo models.
Does Navitoclax (ABT-263) Have FDA Approval?
As of March 18, 2025, Navitoclax (ABT-263) does not have FDA approval for clinical use in humans.
It remains an investigational drug primarily utilized in preclinical and early-phase clinical research.
Regulatory Status of Navitoclax
Preclinical and Clinical Trials:
In Phase I/II clinical trials, Navitoclax has been studied for conditions such as chronic lymphocytic leukemia (CLL) and small-cell lung cancer (SCLC). However, its development faced challenges, including dose-limiting side effects such as thrombocytopenia (low platelet counts), which hindered progression to later-phase trials.
A 2023 trial highlighted its potential in combination therapies (e.g., with Venetoclax for AML), but these studies remain investigational1.
FDA Drug Database:
The U.S. FDA Drugs Database (last updated March 16, 2025) does not list Navitoclax as an approved therapeutic agent. The database includes all FDA-approved drugs, and searching for “Navitoclax” or “ABT-263” yields no results.
Comparison to Approved Bcl-2 Inhibitors:
Venetoclax (ABT-199), a related Bcl-2 inhibitor, received FDA approval for the treatment of CLL and AML in 2016. Navitoclax, however, targets multiple Bcl-2 family proteins (Bcl-2, Bcl-xL, Bcl-w), leading to broader toxicity concerns that have delayed its approval.
While Navitoclax is not FDA-approved, it remains a valuable tool for oncology research.
Researchers and reagent companies can access it through specialized suppliers for preclinical studies.
For updates on its regulatory status, consult the FDA Drugs Database.
Why Hasn’t Navitoclax Been Approved by FDA?
Toxicity Profile: Navitoclax’s inhibition of Bcl-xL leads to thrombocytopenia, a significant barrier to its clinical use. Mitigation strategies (e.g., intermittent dosing) are still under investigation.
Niche Application: Its mechanism is better suited to research on drug-resistant cancers than to broad therapeutic use.
Focus on Derivatives: AbbVie and other companies are developing next-generation Bcl-2 inhibitors with enhanced specificity (e.g., Bcl-xL degraders) to address the limitations of Navitoclax.
Note: The FDA recently approved expanded uses for other drugs, such as eculizumab for pediatric myasthenia gravis, underscoring the dynamic nature of regulatory approvals.
Navitoclax may follow a similar path if future trials address its safety concerns.
What Are the Side Effects of Navitoclax?
While Navitoclax is not used clinically in humans outside trials, preclinical studies highlight manageable side effects:
Thrombocytopenia:
Bcl-xL inhibition in platelets causes transient drops in platelet counts. Strategies include intermittent dosing or co-administration with thrombopoietin agonists.
Gastrointestinal Distress:
Nausea and diarrhea are observed in murine models, typically in a dose-dependent manner.
Fatigue:
Mild lethargy was reported in in vivo studies.
Mitigation Strategies:
Dose optimization (e.g., 50–100 mg/kg/day in mice).
Combination regimens to lower effective doses.
Current Research on Navitoclax
Recent studies (2022–2023) underscore Navitoclax’s expanding role:
Overcoming Venetoclax Resistance: A 2023 Blood study demonstrated that Navitoclax resensitizes AML cells to Venetoclax by targeting Mcl-1 co-resistance.
Solid Tumor Breakthroughs: Research in Nature Cancer highlighted the efficacy of this approach in TP53-mutated SCLC when combined with ATR inhibitors.
Senolytic: Emerging interest in Navitoclax’s ability to clear senescent cells, potentially combating age-related diseases.
Navitoclax in Clinical Trials
Though Navitoclax itself has faced challenges in clinical translation (e.g., thrombocytopenia), its derivatives and combinations show promise:
Phase I/II Trials: Early trials in CLL and SCLC confirmed its apoptosis-inducing activity but noted dose-limiting thrombocytopenia.
Combination Therapies:
Navitoclax + Ruxolitinib: For myelofibrosis (NCT03222609).
Navitoclax + Osimertinib: For EGFR-mutant NSCLC (NCT02520778).
Future Directions: Next-gen Bcl-2 inhibitors with improved specificity (e.g., Bcl-xL degraders) are under development.
How to Source High-Quality Navitoclax?
For researchers and reagent companies, quality is paramount:
Purity Standards:
Opt for ≥98% purity (HPLC-verified).
Supplier Certifications:
Ensure ISO 9001 compliance and batch-specific COAs.
Bulk Purchasing:
Many suppliers offer discounts for orders exceeding 10 grams.
Red Flags:
Lack of solubility data.
Missing safety data sheets (SDS).
Storage and Handling of Navitoclax
Best Practices:
Storage: -20°C in airtight, light-protected vials.
Reconstitution: Use DMSO for stock solutions (stable for 6 months at -20°C).
Incompatibilities: Avoid strong oxidizing agents.
Stability Data:
| Condition | Stability Period |
|---|---|
| Lyophilized Powder | 24 months |
| DMSO Solution | 6 months |
Navitoclax vs. Other Bcl-2 Inhibitors
| Items | Navitoclax (ABT-263) | Venetoclax (ABT-199) |
|---|---|---|
| Targets | Bcl-2, Bcl-xL, Bcl-w | Bcl-2 |
| Oral Bioavailability | Yes | Yes |
| Key Toxicity | Thrombocytopenia | Tumor lysis syndrome |
| Research Use | Broad-spectrum | CLL/AML-focused |
Takeaway: Navitoclax offers broader target coverage, making it ideal for studying Bcl-xL-dependent cancers.
ABT-263 Applications in Cancer Research
Liquid Tumors:
Navitoclax + R-CHOP in DLBCL models reduces relapse rates.
Solid Tumors:
Synergizes with PARP inhibitors in BRCA-mutated breast cancer.
Patient-Derived Xenografts (PDX):
Used to mimic human tumor microenvironments.
Other FAQs About Navitoclax
Q: What solvents are compatible with Navitoclax?
A: DMSO, ethanol, or PBS (pH 7.4). Avoid aqueous buffers for long-term storage.
Q: Can Navitoclax be used in zebrafish models?
A: Yes, but doses must be optimized (typically 1–5 μM).
Q: Is Navitoclax suitable for high-throughput screening?
A: Absolutely—its IC50 of <10 nM in many cell lines ensures robust activity.
Q: Do you offer technical support for experimental design?
A: Reputable suppliers provide protocol optimization guides and scientist consultations.
Why Navitoclax Remains a Research Cornerstone
Despite clinical hurdles, Navitoclax’s versatility in targeting multiple Bcl-2 proteins ensures its relevance in apoptosis research.
For reagent companies, supplying high-purity Navitoclax meets the growing demand for tools to combat drug-resistant cancers.
Disclaimer:
This blog post is for informational purposes and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
